December 7, 2021

Findings from the expansion of a phase 1 study of tinostamustine in patients with relapsed/refractory (R/R) Hodgkin Lymphoma (HL) will be presented at the 2021 ASH Annual Meeting & Exposition. Tinostamustine is a developing therapy designed to improve drug access to DNA strands, induce DNA damage, and counteract DNA repair in cancer cells. A dose-escalation study...

In this MD Newsline exclusive interview with neurologist Dr. Mitzi Williams, we discuss barriers to NMOSD treatment adherence and the latest research on treatments for NMOSD. MD Newsline: What do you think are the biggest barriers to NMOSD treatment adherence?  Dr. Mitzi Williams: “The biggest barriers to NMOSD treatment are very similar to those that...

In this MD Newsline exclusive interview with neurologist Dr. Mitzi Williams, we discuss how NMOSD differs from MS. We also discuss Dr. Williams’s treatment strategy for NMOSD. MD Newsline: How does NMOSD differ from multiple sclerosis (MS)? Dr. Mitzi Williams: “NMOSD can often be diagnosed with an antibody test, whereas MS cannot. Also, NMOSD primarily...

In this MD Newsline exclusive interview with neurologist Dr. Mitzi Williams, we discuss neuromyelitis optica spectrum disorder (NMOSD), why it is an important health issue, and how it differs from multiple sclerosis and anti-MOG syndrome. MD Newsline: Can you explain what neuromyelitis optica spectrum disorder (NMOSD) is and why it is an important health issue? ...